Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

Edward Li, PharmD, MPH, BCOP, Associate Professor, University of New England College of Pharmacy, discusses oncology targeting biosimilars that are nearing approval

Published: 04 May 2017

Recent Videos

video

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

Dr. Figlin regarding the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.

video

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

Dr. Figlin offers opinion on whether the convenience of oral TKIs influences treatment decisions in advanced renal cell cancer patients.

video

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

Dr. Figlin on how checkpoint inhibitors figure into treatment algorithms for unresectable 1st line renal cell carcinoma (RCC) patients

video

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

Dr. Figlin on deciding which metastatic RCC patients should get a TKI as first line therapy

video

Robert A. Figlin, MD, provides perspective on I-O failures

Dr. Figlin considers the best course of action if a newly diagnosed advanced renal cell carcinoma (RCC) patient receives nivolumab ...

video

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

Dr. Stadler on deciding which metastatic renal cell carcinoma (mRCC) patients should receive a TKI as 1st line therapy

video

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

Dr. Stadler elaborates on how an advanced renal cell carcinoma (RCC) patient should be treating in the 2nd line setting ...

video

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

Dr. Stadler comments on whether TKIs used in the treatment of renal cell carcinoma (RCC) are interchangeable and which seem ...

video

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

Dr. Stadler elaborates on the outcomes of the PROSPER and SPARTAN studies in non-metastatic castrate-resistant prostate cancer

video

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

Dr. Stadler tells us how immunotherapy is being integrated into castrate resistant prostate cancer treatment algorithms

Related Videos

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms